Capricor Therapeutics (NASDAQ:CAPR) Shares Up 10.6% – Still a Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR) traded up 10.6% during trading on Thursday . The stock traded as high as $20.35 and last traded at $20.16. 285,948 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 1,141,996 shares. The stock had previously closed at $18.23.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on CAPR shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler initiated coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Capricor Therapeutics Stock Up 4.5 %

The business’s 50-day simple moving average is $13.81 and its two-hundred day simple moving average is $8.00. The firm has a market capitalization of $894.58 million, a price-to-earnings ratio of -21.18 and a beta of 4.00.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Sell-side analysts anticipate that Capricor Therapeutics Inc will post -1.17 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Institutional investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. increased its holdings in shares of Capricor Therapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after acquiring an additional 13,762 shares during the last quarter. SG Americas Securities LLC purchased a new position in Capricor Therapeutics in the third quarter valued at approximately $133,000. Marshall Wace LLP acquired a new stake in Capricor Therapeutics during the second quarter worth approximately $426,000. Renaissance Technologies LLC lifted its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after buying an additional 84,350 shares during the last quarter. Finally, Main Street Financial Solutions LLC boosted its holdings in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.